China's CBMG Aims For Large-Scale CAR-T Capacity
CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large scale in China, at a standard that matches the US.
You may also be interested in...
Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.